KG&L Capital Management’s Cardlytics CDLX Stock Holding History

KG&L Capital Management’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-464	Closed	-$389K	–	146
2021 Q3	$389K	Buy	+464	New	+$471K	0.17%	100

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

KG&L Capital Management's CDLX Position: Q4 2021 in Review

KG&L Capital Management sold out of Cardlytics (CDLX) in Q4 2021, closing a stake of 464 shares — an estimated $389K sold.

KG&L Capital Management first reported a position in CDLX in Q3 2021 and held it in 1 quarter. The position peaked at $389K in Q3 2021. 163 funds tracked by Wall St. Rank hold CDLX as of Q4 2021.

KG&L Capital Management reported no remaining Cardlytics position as of Q4 2021 after selling out during the quarter.
KG&L Capital Management sold 464 Cardlytics shares in Q4 2021, an estimated $389K.
KG&L Capital Management first reported a position in Cardlytics in Q3 2021 and held it in 1 quarter.
KG&L Capital Management's Cardlytics position peaked at $389K in Q3 2021.
163 funds tracked by Wall St. Rank held Cardlytics as of Q4 2021.

Based on KG&L Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.